Mesenchymal Stem Cells Market

Market Overview:

The global mesenchymal stem cells market size reached US$ 2.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 6.16 Billion by 2028, exhibiting a growth rate (CAGR) of 13.06% during 2023-2028. The rising prevalence of various chronic diseases among the masses, the continual development of novel therapies, and extensive research and development (R&D) activities are some of the major factors propelling the mesenchymal stem cells market.

Mesenchymal stem cells (MSCs) are a type of adult stem cell that holds immense promise in the field of regenerative medicine. They are found in various tissues throughout the body, including bone marrow, adipose tissue (fat), umbilical cord blood, and dental pulp. MSCs have the remarkable ability to differentiate into multiple cell types, such as bone cells (osteoblasts), cartilage cells (chondrocytes), muscle cells (myocytes), and fat cells (adipocytes). Additionally, they also secrete a plethora of bioactive molecules, including growth factors, cytokines, and extracellular vesicles, which play crucial roles in tissue regeneration and repair. These paracrine factors can stimulate the proliferation and differentiation of nearby cells, promote angiogenesis (formation of new blood vessels), reduce scar formation, and enhance tissue remodeling. Due to their regenerative potential and immunomodulatory properties, MSCs have been investigated for a wide range of therapeutic applications.

The growing healthcare expenditure majorly drives the global market. This can be supported by the rising prevalence of chronic diseases among the masses. As the global population ages and chronic diseases become more prevalent, the demand for effective therapies that address the underlying causes of these conditions is constantly increasing. MSCs have shown remarkable capabilities in promoting tissue repair and regeneration, making them a potential solution for conditions, which is acting as another growth-inducing factor. Furthermore, the limited efficacy and safety concerns associated with traditional treatment options has driven the search for alternative approaches, thus creating a positive market outlook. Some of the other factors driving the market include continual improvements in healthcare infrastructure and the growing awareness among the masses.

Mesenchymal Stem Cells Market Trends/Drivers

Widespread Preference for Regenerative Medicine

MSCs have emerged as a promising tool for regenerative medicine. They can be isolated from various sources, including bone marrow, adipose tissue, umbilical cord, and dental pulp. The growing popularity of MSCs for repairing damaged or degenerated tissues due to their ability to differentiate into multiple tissue types and their immunomodulatory properties is significantly supporting the market. The market for regenerative medicine is projected to grow in the near future as the demand for effective treatments for chronic diseases and tissue injuries is continually increasing. In addition, the widespread adoption of MSCs to promote the healing of fractures, cartilage defects, ligament injuries, and tendon damage is also positively influencing the market. By injecting MSCs directly into the affected area, it is possible to enhance tissue repair and reduce inflammation, leading to improved outcomes and faster recovery times. As the aging population increases and the prevalence of musculoskeletal conditions rises, the demand for MSC-based therapies in orthopedics is expected to grow significantly.

Increasing Incidences of Autoimmune and Inflammatory Diseases

The rising adoption of MSCs for the treatment of autoimmune and inflammatory diseases is majorly driving the market. These cells can suppress immune responses, reduce inflammation, and promote tissue regeneration. The treatment of various conditions, such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, and systemic lupus erythematosus, can potentially benefit from MSC-based therapies. The market for autoimmune and inflammatory disease treatments is substantial and continues to expand, thereby offering significant opportunities for MSC-based interventions. Additionally, MSCs can promote angiogenesis, enhance cardiac tissue repair, and improve cardiac function. The market for cardiovascular therapeutics is extensive, and MSC-based treatments have the potential to revolutionize the management of these conditions.

Augmenting Demand for Effective Cancer and Neurological Therapies

While MSCs are not directly used to target cancer cells, they can be genetically modified to deliver anticancer agents or enhance the efficacy of existing therapies. This is catalyzing the demand for MSCs as it possess the ability to migrate toward tumor sites. In addition, MSCs can inhibit tumor growth, suppress angiogenesis, and modulate the immune system to support anticancer responses. The cancer therapeutics market holds massive growth opportunities, and MSCs offer can assist in several innovative and targeted treatment approaches. MSCs have demonstrated potential in the treatment of numerous neurological disorders, such as stroke, Parkinson's disease, Alzheimer's disease, and spinal cord injuries. These cells can secrete growth factors and anti-inflammatory molecules, promote neuronal regeneration, and modulate the immune response in the central nervous system. The neurological disorders market is substantial and continues to grow as the aging population are susceptible to developing neurodegenerative conditions.

Mesenchymal Stem Cells Industry Segmentation

IMARC Group provides an analysis of the key trends in each segment of the global the mesenchymal stem cells market report, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product & services, type, source of isolation, indication, and application.

Breakup by Product & Services:

• Products
  • Cells and Cell Lines
  • Kits, Media, and Reagents
  • Others
• Services
   

Products dominate the mesenchymal stem cells market

The report has provided a detailed breakup and analysis of the mesenchymal stem cells market based on the product & services. This includes products (cells and cell lines, kits, media, and reagents, and others), and services. According to the report, products represented the largest segment.

The increasing prevalence of chronic diseases, such as cardiovascular disorders, orthopedic conditions, and autoimmune diseases, has created an augmenting need for innovative and effective treatment options, including MSC products.

Along with this, the rising need for a consistent and reliable supply of high-quality MSCs and MSC-derived products is fuelling the demand for cells and cell lines in this field. Furthermore, continual advancements in biotechnology and cell culture techniques have facilitated the large-scale production of MSC products, which is also contributing to the market in this segment.

On the other hand, with ongoing research and clinical trials exploring new indications and treatment approaches, the market for services in mesenchymal stem cells is also poised to exhibit significant growth in the coming years.

Breakup by Type:

• Autologous
• Allogeneic
   

Allogeneic represents the leading type in the mesenchymal stem cells market

A detailed breakup and analysis of the mesenchymal stem cells market based on the type has also been provided in the report. This includes autologous and allogeneic. According to the report, allogeneic accounted for the largest market share.

The allogeneic MSCs offer significant advantages over autologous MSCs as they can be derived from healthy, young donors and expanded in large quantities, ensuring a consistent and scalable cell supply. This eliminates the need for invasive and time-consuming procedures to obtain cells from each patient individually, thereby propelling the market.

Another important driver for the market growth in this segment is the potential for off-the-shelf availability, allowing for immediate administration without the need for complex and costly manufacturing processes. Furthermore, allogeneic MSCs have shown promising results in various clinical applications, including regenerative medicine, immunomodulation, and tissue repair, thus creating a strong demand for their use in treating diverse medical conditions.

On the other hand, autologous MSCs enable personalized medicine approaches as the cells can be tailored to the specific needs of each patient. This customization allows for a targeted treatment approach, potentially leading to better patient responses and outcomes.

Breakup by Source of Isolation:

• Bone Marrow
• Cord Blood
• Peripheral Blood
• Fallopian Tube
• Fetal Liver
• Lung
• Adipose Tissues
   

Bone marrow dominates the mesenchymal stem cells market

The report has provided a detailed breakup and analysis of the mesenchymal stem cells market based on the source of isolation. This includes bone marrow, cord blood, peripheral blood, fallopian tube, fetal liver, lung, and adipose tissues. According to the report, bone marrow represented the largest segment.

MSCs derived from bone marrow possess unique regenerative properties, making them an attractive option for treating these conditions. Moreover, continual advancements in cell culture techniques and bioprocessing technologies have improved the scalability and quality of MSC production from bone marrow, making them more accessible and commercially viable. This is providing a positive outlook for the market in this segment.

On the contrary, cord blood-derived MSCs have shown promise in regenerative medicine, particularly in the treatment of hematological disorders, autoimmune diseases, and tissue repair. Similarly, fallopian tube-derived MSCs are useful in wound healing, and reproductive medicine. These segments are poised to exhibit substantial growth in the upcoming future.

Breakup by Indication:

• Bone and Cartilage Repair
• Cardiovascular Disease
• Inflammatory and Immunological Diseases
• Liver Diseases
• Cancer
• GvHD
• Others
   

Cardiovascular disease dominates the mesenchymal stem cells market

The report has provided a detailed breakup and analysis of the mesenchymal stem cells market based on the indication. This includes bone and cartilage repair, cardiovascular disease, inflammatory and immunological diseases, liver diseases, cancer, GvHD, and others. According to the report, cardiovascular disease represented the largest segment.

The rising prevalence of cardiovascular diseases, including heart failure, ischemic heart disease, and myocardial infarction, is fuelling the requirement for effective and sustainable treatment options. Due to the pressing need for innovative therapeutic approaches to combat cardiovascular diseases among the masses, there has been an augmenting demand for MSC-based therapies. Mesenchymal stem cells possess unique properties that make them an attractive option for cardiovascular disease treatment, which is acting as another growth-inducing factor.  

MSCs possess immunomodulatory properties and have the ability to suppress the immune response and regulate the activity of various immune cells. Additionally, MSCs have shown promise in managing GvHD by modulating the immune response and suppressing inflammation. Also, mesenchymal stem cells (MSCs) are adopted in bone and cartilage repair due to their ability to differentiate into bone and cartilage cells. MSC-based therapies are also being explored as potential treatments for other conditions, such as osteoarthritis, osteoporosis, and cartilage defects.

Breakup by Application:

• Disease Modelling
• Drug Development and Discovery
• Stem Cell Banking
• Tissue Engineering
• Toxicology Studies
   

Disease modelling dominates the mesenchymal stem cells market

The report has provided a detailed breakup and analysis of the mesenchymal stem cells market based on the application. This includes disease modelling, drug development and discovery, stem cell banking, tissue engineering, and toxicology studies. According to the report, disease modelling represented the largest segment.

The growing interest and investments in the field of regenerative medicine and cell-based therapies is fuelling the market for disease modeling in MSCs, as researchers and pharmaceutical companies recognize the potential impact of these models in drug discovery and precision medicine. The growing need for disease modeling in MSCs can be attributed to better disease understanding, the pursuit of innovative therapeutic strategies, and the increasing focus on personalized medicine.

On the contrary, mesenchymal stem cells (MSCs) play a crucial role in drug development and discovery. They are used as in vitro models to evaluate the safety and efficacy of new drugs and potential therapeutic compounds. Moreover, stem cell banks also offer individuals the opportunity to store their own MSCs for potential therapeutic use in the future. These banks provide long-term storage of MSCs derived from various sources, such as cord blood, adipose tissue, and bone marrow.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America exhibits a clear dominance, accounting for the largest mesenchymal stem cells market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.   

The aging population in North America is driving the need for effective treatments for age-related degenerative diseases. MSCs are demonstrating the ability to differentiate into various cell types, making them a valuable tool in combating age-related conditions. Additionally, the supportive regulatory environment in North America, including streamlined approval processes and favorable reimbursement policies, is encouraging extensive research and development in the field of MSCs.

The favorable regulatory environment in many Asia Pacific countries, coupled with the availability of skilled healthcare professionals and advanced research facilities in the region, is contributing to the market in this region. Additionally, the rising geriatric population in countries like Japan, China, and South Korea has fueled the demand for advanced therapies that can address age-related health issues. This is expected to drive the demand for MSCs in Asia Pacific in the near future.

Competitive Landscape

The global mesenchymal stem cells market is experiencing significant growth with the rising investments by top players in the development of MSC-based therapies on account of the growing demand for effective and innovative treatments among the masses. Companies are developing and commercializing MSC-based cell therapies for specific indications, such as cancer immunotherapy, diabetes treatment, or bone regeneration, which is driving the demand for mesenchymal stem cells. In addition, key players are leveraging the unique characteristics of MSCs to provide screening services, develop disease models, or offer preclinical testing platforms for pharmaceutical companies, which is acting as another growth-inducing factor. Apart from this, leading mesenchymal stem cell companies are providing clinical trial services, including protocol design, patient recruitment, regulatory support, and data analysis, specifically tailored for MSC-based therapies, which, in turn, is impacting the overall market.

The report has provided a comprehensive analysis of the competitive landscape in the global mesenchymal stem cells market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• ATCC
• Axol Bioscience Ltd.
• Cell Applications Inc.
• Celprogen Inc.
• Cyagen Biosciences Inc.
• Lonza Group AG
• Merck KGaA
• PromoCell GmbH
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific Inc.

Recent Developments

• On February 2023, ATCC, the world’s premier biological materials management and standards organization, and U.S. Pharmacopeia (USP) announced a long-term, multi-year strategic partnership to jointly provide co-branded reference materials and reference standards that will help advance the quality and development of biologic medicines and therapies.
• Celprogen launched 3D printed human brain organelle model system for neurological disease research that may be used to develop novel drugs. The current invention pertains to Celprogen's 3D organ printing programs, which identify potential applications in the transplantation of major organ systems in the future. For toxicological and drug discovery research, Celprogen is now verifying the 3D-printed human heart, pancreas, liver, hair follicle, and brain.
• Axol Bioscience Ltd. merged with Censo Biotechnologies to offer human iPSC-derived cells and services to the biopharma industry. Axol's mission is to be a valued partner to its customers, delivering high-quality and consistent iPSC-derived cells, models, and assay data to drive R&D and drug discovery efforts.

Mesenchymal Stem Cells Market Report Scope:

Report Coverage:

Key Questions Answered in This Report:

• How has the global mesenchymal stem cells market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global mesenchymal stem cells market?
• What is the impact of each driver, restraint, and opportunity on the global mesenchymal stem cells market?
• What are the key regional markets?
• Which countries represent the most attractive mesenchymal stem cells market?
• What is the breakup of the market based on the product & services?
• Which is the most attractive product & services in the mesenchymal stem cells market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the mesenchymal stem cells market?
• What is the breakup of the market based on the source of isolation?
• Which is the most attractive source of isolation in the mesenchymal stem cells market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the mesenchymal stem cells market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the mesenchymal stem cells market?
• What is the competitive structure of the global mesenchymal stem cells market?
• Who are the key players/companies in the global mesenchymal stem cells market?

Key Benefits for Stakeholders

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the mesenchymal stem cells market from 2017-2028.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global mesenchymal stem cells market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the mesenchymal stem cells industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.